Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease

International Journal of Cardiology

Volumn 209, Issue , 2016, Pages 181-183

  Noseworthy, Peter A ^a   Yao, Xiaoxi ^a   Shah, Nilay D ^a,b,c   Gersh, Bernard J ^a  

^a MAYO CLINIC   (United States)

^b Department of Health Services Research ^*  (United States)

^c OPTUM   (United States)

Author keywords

Bleeding; NOAC; Stroke; Valvular heart disease; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART VALVE PROSTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE STENOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VALVULAR HEART DISEASE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; FACTUAL DATABASE; HEART VALVE DISEASES; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DATABASES, FACTUAL; FEMALE; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN K; WARFARIN; YOUNG ADULT;

EID: 84961714979     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.02.005     Document Type: Article

References (10)

1. ESC Committee for Practice Guidelines 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association Eur. Heart J. 33 2012
2. V. Fuster, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, and et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol. 38 2001 1266-1266
3. V. Fuster, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, and et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol. 57 2011 e101 e198
4. C.T. January, L.S. Wann, J.S. Alpert, H. Calkins, J.E. Cigarroa, J.B. Conti, and et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J. Am. Coll. Cardiol. 64 2014 e1 e76
5. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, H.-C. Diener, W. Hacke, and et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation Europace 2015 euv309
6. P.J. Wallace, N.D. Shah, T. Dennen, P.A. Bleicher, and W.H. Crown Optum Labs: building a novel node in the learning health care system Health Affairs 33 2014 1187 1194
7. M.D. Ezekowitz, H. Parise, R. Nagarakanti, H. Noack, M. Brueckmann, A. Clemens, and et al. Comparison of dabigatran versus warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY® trial J. Am. Coll. Cardiol. 63 2014
8. G. Breithardt, H. Baumgartner, S.D. Berkowitz, A.S. Hellkamp, J.P. Piccini, S.R. Stevens, and et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial Eur. Heart J. 2014 ehu305
9. A. Avezum, R.D. Lopes, P.J. Schulte, F. Lanas, B.J. Gersh, M. Hanna, and et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial Circulation 132 2015 624 632
10. R. De Caterina, and A.J. Camm What is 'valvular' atrial fibrillation? A reappraisal Eur. Heart J. 35 2014 3328 3335